The Latest Breaking News from BDTX

Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path

Black Diamond Therapeutics (NASDAQ:BDTX) is positioning its lead oncology drug candidate, silevertinib, as a potential treatment for non-small cell lung cancer patients with non-classical EGFR mutations, Chief Executive Officer Mark Velleca said during a Jefferies fireside chat following the company

MarketBeat · Jun 6

Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study

Black Diamond Therapeutics (NASDAQ:BDTX) reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the investigational therapy produced a preliminary median progression-free survival of 15.2 months in the study coh

MarketBeat · May 21

Black Diamond Cuts 30% Of Its Workforce, Discontinues Drug From its 'MasterKey' Pipeline

Black Diamond Therapeutics Inc (NASDAQ: BDTX) is realigning its resources to extend its cash runway into the third quarter of 2024.

Benzinga · Apr 25, 2022